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EBV+ B-cell polymorphic lymphoproliferative disorder of the lip in a patient with
advanced chronic lymphocytic leukemia
Steven Townsend, BS, Gabrielle Robinson, MD, Ben J. Friedman, MD
Henry Ford Health System, Department of Dermatology, Detroit, MI

History
• A 77 year-old white male with a history of advanced chronic
lymphocytic leukemia (CLL) on rituximab and bendamustine
presented with a 6-week history of a growing, tender nodule
on his right lower lip.
• He had previously failed an empiric trial of acyclovir for
suspected herpes labialis.

Differential and Clinical Course
• Differential diagnosis included EBV+ B-cell polymorphic
lymphoproliferative disorder (B-PMLD), EBV+
mucocutaneous ulcer (MCU), EBV+ marginal zone lymphoma
(MZL), and cutaneous CLL.
• Unfortunately, the patient expired a few weeks after
presentation from complications of his CLL.

Examination
• Involving the right lower lip, there was an ~ 3 x 2 cm nodule
with central hemorrhagic crust.

Figure 2. H&E, Original Magnification, 50x

Figure 1. ~ 3 x 2 cm nodule with central ulcer

Figure 3. The polymorphous infiltrate is Figure 4. EBV positivity (EBER
seen dissecting through skeletal muscle
ISH, Original Magnification, 200x)
fibers (H&E, Original Magnification, 200x)

Histopathology, Immunohistochemistry, and Molecular Studies
A biopsy via deep saucerization was performed revealing a dense perivascular and interstitial infiltrate of lymphocytes and
plasmacytoid cells extending from the dermis through the subcutis and skeletal muscle plane. Plasmacytoid cells comprised the majority
of the infiltrate. Rare immunoblast-like cells and atypical plasmacytoid cells were observed.
•
•
•
•

CD79a- Diffusely positive
CD3- Highlighted smaller population of cells than CD79a
CD5- Similar staining pattern to CD3
CD20- Rare clusters of positive cells that highlighted the
immunoblastic cells
• CD30- Rare positive cells
• Pax5- Similar staining pattern to CD20
• BCL6 and CD56- Negative

• CD23- Rare clusters of positive cells; no follicular dendritic cell
meshwork appreciated
• Kappa-to-lambda ratio of ~1:10, consistent with lambda light
chain restriction
• IgA, IgG, IgM- Predominantly IgA positive cells with fewer IgG
and rare IgM positive cells.
• EBV-encoded RNA in situ hybridization (EBER ISH)- Diffusely
positive
• IGH B-cell gene rearrangement: Failed to detect monoclonal
population

Discussion
• EBV+ B-PMLD is a rare lymphoid neoplasm that typically
occurs in post-transplant and other immunodeficiency settings.
Lesions are morphologically heterogenous and can result in
destructive masses that may mimic large B-cell or classical
Hodgkin lymphomas.1,2,3
• Histologically, B-PLMDs exhibit a full range of B-cell
maturation stages including small- to medium-sized
lymphocytes, plasma cells, and immunoblasts. Clonality is
usually demonstrable via IGH gene rearrangement studies and/or
evaluation of lambda & kappa for light chain restriction.1,2
• First line treatment is reduction of immunosuppression, but more
aggressive immunotherapy, chemotherapy, or radiation therapy
may be required for cases that do not regress or when reversal of
immunosuppression is not feasible. Fatal dissemination of disease
may still occur despite intervention.1,2
• EBV+ B-PMLD falls on a spectrum of B-cell lymphoproliferative
disorders that are often challenging to definitively distinguish
given overlapping morphologic and immunophenotypic findings.
• EBV+ MCU represents a localized form of immunodeficiency
that most commonly presents as a sharply demarcated ulcer on
the oropharyngeal mucosa. Unlike EBV+ B-PMLD, EBV+ MCU
typically affects immunocompetent individuals, has more
conspicuous CD30+ immunoblasts than plasmacytoid cells, and
often lacks significant nodularity.1,2
• Cutaneous EBV+ MZL is a rarely reported immunodeficiencyassociated lymphoma.4 While entity cannot be entirely excluded
in this case, cutaneous lesions of EBV+ MZL would be expected
to show some evidence of pre-existing lymphoid follicles.4
• Cutaneous CLL was not favored given the distinctly plasmacytoid
differentiation of the tumor. Furthermore, the patient’s CLL had
demonstrated kappa light chain restriction as opposed to the
lambda restriction evident in this lesion.5
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